Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Homogenizing Sn-Pb Distribution Through A-Site MA Cations for Efficient All-Perovskite Tandem Solar Cells.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Tailoring Zn<sub>2</sub>SnO<sub>4</sub>inverse spinel via Co doping: enhanced two-electron water oxidation for efficient H<sub>2</sub>O<sub>2</sub>electrosynthesis.

Nanotechnology·2026
Same author

Optimization and flavor characterization of milk tea formulated with large-leaf yellow tea and tangerine peel: A combined fuzzy mathematical, response surface, and multimodal sensory approach.

Food chemistry: X·2026
Same author

The first near telomere-to-telomere genome assembly of Panulirus homarus homarus.

Scientific data·2026
Same author

GhZAT10 integrates jasmonic acid and ethylene pathways to synergistically regulate the GhKUP3aD-mediated high-affinity K<sup>+</sup> uptake in Gossypium hirsutum.

Science bulletin·2026
Same author

Extended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study.

Journal of gynecologic oncology·2026

相关实验视频

Updated: Jun 11, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

467

纳米粒子介导的通用CAR-T疗法

Mingliang Fan1, Jiayu Zheng1, Yue Huang1

  • 1School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.

International journal of pharmaceutics
|September 30, 2024
PubMed
概括

使用纳米载体的通用CAR-T疗法为传统方法提供了具有成本效益的替代方案. 这种方法可以在体内产生CAR-T细胞,简化制造并提高癌症免疫治疗的可访问性.

关键词:
基因输送 基因输送 基因输送脂质纳米颗粒的使用方法纳米颗粒是如何形成的全面的CAR-T疗法

更多相关视频

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

830
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.9K

相关实验视频

Last Updated: Jun 11, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

467
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

830
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

14.9K

科学领域:

  • 免疫学 免疫学 免疫学
  • 生物技术是生物技术.
  • 纳米医学是一种纳米医学.

背景情况:

  • 化学抗原受体 (CAR) -T细胞疗法在血液癌症中取得了成功.
  • 目前的CAR-T疗法需要复杂,昂贵和耗时的ex vivo制造.
  • 有限的可访问性和高成本阻碍了对自性CAR-T治疗的广泛采用.

研究的目的:

  • 探索纳米载体介导的基因传递,用于在位的CAR-T细胞生成.
  • 提出一个"现成"的普遍CAR-T治疗策略.
  • 为了克服传统的Autologous CAR-T细胞制造的局限性.

主要方法:

  • 利用生物相容的纳米载体进行向的基因传递.
  • 开发纳米粒子介导的CAR-T细胞的现场生成.
  • 研究通用CAR-T疗法的潜力.

主要成果:

  • 纳米载体传递CAR基因使得体内CAR-T细胞生成成为可能.
  • 这一策略大大简化了制造过程.
  • 预计将降低成本和缩短管理时间.

结论:

  • 纳米粒子介导的在位CAR-T细胞生成是通用CAR-T疗法的有前途的方法.
  • 这种方法为自主CAR-T制造提供了成本效益高且可访问的替代方案.
  • 该策略有可能提高CAR-T癌症免疫治疗的流行率和疗效.